DE602007008691D1 - Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind - Google Patents

Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind

Info

Publication number
DE602007008691D1
DE602007008691D1 DE602007008691T DE602007008691T DE602007008691D1 DE 602007008691 D1 DE602007008691 D1 DE 602007008691D1 DE 602007008691 T DE602007008691 T DE 602007008691T DE 602007008691 T DE602007008691 T DE 602007008691T DE 602007008691 D1 DE602007008691 D1 DE 602007008691D1
Authority
DE
Germany
Prior art keywords
bace inhibitors
cyclic sulphones
medicaments
sulphones
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007008691T
Other languages
English (en)
Inventor
Heinrich Rueeger
Clive Mccarthy
Henrik Moebitz
Jean-Michel Rondeau
Marina Tintelnot-Blomley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602007008691D1 publication Critical patent/DE602007008691D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602007008691T 2006-02-14 2007-02-14 Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind Active DE602007008691D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602951.6A GB0602951D0 (en) 2006-02-14 2006-02-14 Organic Compounds
PCT/EP2007/051454 WO2007093621A1 (en) 2006-02-14 2007-02-14 Cyclic sulfones useful as bace inhibitors

Publications (1)

Publication Number Publication Date
DE602007008691D1 true DE602007008691D1 (de) 2010-10-07

Family

ID=36141810

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007008691T Active DE602007008691D1 (de) 2006-02-14 2007-02-14 Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind

Country Status (13)

Country Link
US (1) US20090099207A1 (de)
EP (1) EP1989194B1 (de)
JP (1) JP2009526820A (de)
KR (1) KR20080093049A (de)
CN (1) CN101384580A (de)
AT (1) ATE478858T1 (de)
AU (1) AU2007216463A1 (de)
BR (1) BRPI0707812A2 (de)
CA (1) CA2637857A1 (de)
DE (1) DE602007008691D1 (de)
GB (1) GB0602951D0 (de)
RU (1) RU2008136762A (de)
WO (1) WO2007093621A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20100061805A (ko) * 2007-08-23 2010-06-09 노파르티스 아게 Bace 억제제로서 유용한 아미노벤질-치환된 시클릭 술폰
JP2011527311A (ja) * 2008-07-10 2011-10-27 ノバルティス アーゲー Bace阻害薬として有用なアミノベンジル置換環状スルホン誘導体
EP2485590B1 (de) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Heterozyklische pentafluorsulfur-imin-verbindungen als bace-1-hemmer sowie zusammensetzungen damit und ihre verwendung
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
KR100869061B1 (ko) * 2000-12-13 2008-11-17 와이어쓰 베타 아밀로이드 생성의 헤테로고리 술폰아미드 저해제

Also Published As

Publication number Publication date
US20090099207A1 (en) 2009-04-16
CA2637857A1 (en) 2007-08-23
JP2009526820A (ja) 2009-07-23
AU2007216463A1 (en) 2007-08-23
WO2007093621A1 (en) 2007-08-23
CN101384580A (zh) 2009-03-11
EP1989194B1 (de) 2010-08-25
KR20080093049A (ko) 2008-10-17
EP1989194A1 (de) 2008-11-12
GB0602951D0 (en) 2006-03-29
BRPI0707812A2 (pt) 2011-05-10
ATE478858T1 (de) 2010-09-15
RU2008136762A (ru) 2010-03-20

Similar Documents

Publication Publication Date Title
SV2010003463A (es) Compuestos organicos
EA201170772A1 (ru) Органические соединения
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
EA200870116A1 (ru) Бициклические гетероарильные соединения
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2007025709A3 (en) Organic compounds
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MA32505B1 (fr) 5-alcynyl-pyrimidines
DE602006009789D1 (de) Acetylenderivate
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств